P. Chang

发表

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study

A. Traboulsee, A. al‐Sabbagh, R. Bennett, 2008, BMC neurology.

Randomized, comparative study of interferon β-1a treatment regimens in MS

D. Goodin, B. Weinshenker, David K.B. Li, 2002, Neurology.

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus

D. Isenberg, P. Chang, D. Wallace, 2017, Arthritis & rheumatology.

Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.

P. Chang, O. Goker-Alpan, Y. Lien, 2015, JIMD reports.

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

R. Schiffmann, P. Chang, Y. Lien, 2014, Orphanet Journal of Rare Diseases.

University of Birmingham Integrated safety profile of atacicept

P. Chang, D. Wofsy, A. Kao, 2019 .

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme

C. Gordon, P. Chang, D. Wofsy, 2019, Rheumatology advances in practice.

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy

R. Schiffmann, P. Chang, N. Longo, 2016, Drug design, development and therapy.

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

P. Chang, F. Bellanti, B. Bartok, 2021, British journal of clinical pharmacology.

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

Geneva, G. Francis, P. Chang, 2005, Neurology.

Growth Hormone, Glutamine, and an Optimal Diet Reduces Parenteral Nutrition in Patients With Short Bowel Syndrome: A Prospective, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

K. Iyer, P. Chang, D. Wilmore, 2005, Annals of surgery.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

P. Vermersch, G. Comi, G. Giovannoni, 2010, The New England journal of medicine.

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Dawn Y. Lim, John C. Greiner, H. Thieme, 2021, Drugs.

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis

S. Patten, G. Francis, P. Chang, 2005, Multiple sclerosis.

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

D. Goodin, David K.B. Li, H. Panitch, 2005, Journal of the Neurological Sciences.

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis

C. Bever, G. Francis, P. Chang, 2005, Journal of Neurology.

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

P. Chang, M. Lopez-Bresnahan, D. Mikol, 2005, Multiple sclerosis.

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

D. Isenberg, P. Chang, E. Morand, 2020, Rheumatology.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

F. Barkhof, B. Uitdehaag, B. Stubinski, 2008, The Lancet Neurology.

Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial

D. Goodin, B. Weinshenker, David K.B. Li, 2002 .

Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial

Viglietta, P. Vermersch, G. Comi, 2009 .

8 Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomisedrandomized, placebo-controlled, phase iib study

D. Isenberg, P. Chang, P. Fraser, 2017, Lupus Science & Medicine.

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

J. Kuusisto, P. Chang, O. Goker-Alpan, 2015, Drug design, development and therapy.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

D. Goodin, David K.B. Li, H. Panitch, 2005, Archives of neurology.

Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS study

J. Oger, J. Oger, G. Francis, 2005, Journal of the Neurological Sciences.

The long‐term safety and tolerability of high‐dose interferon β‐1a in relapsing–remitting multiple sclerosis: 4‐year data from the PRISMS study

P. Chang, P. Rieckmann, J. Abdalla, 2005, European journal of neurology.

Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)

P. Vermersch, G. Comi, G. Giovannoni, 2009 .

Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

P. Vermersch, S. Greenberg, G. Comi, 2009 .

Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Viglietta, P. Vermersch, S. Greenberg, 2009 .